Literature DB >> 29713955

Successful hemostatic management of major surgery for cervical spondylotic myelopathy in a patient with severe factor XI deficiency.

Yoshiyuki Ogawa1, Kunio Yanagisawa2, Yuri Uchiyama2,3, Naoki Akashi2, Tokue Mieda4, Haku Iizuka4, Madoka Inoue5, Reiko Shizuka5, Masami Murakami6, Naomichi Matsumoto3, Hiroshi Handa2.   

Abstract

Factor XI deficiency (FXID) is a rare bleeding disorder caused by mutations in the F11 gene. Spontaneous bleeding in patients with factor XI deficiency is rare, but major bleeding may occur after surgery or trauma. The basic method for hemostatic treatment is replacement of the missing factor using FXI concentrate or fresh frozen plasma (FFP). We report the case of a 72-year-old male with severe FXID who underwent a laminoplasty under sufficient, but minimal, FFP transfusion. Through detailed monitoring of activated partial thromboplastin time (APTT) and FXI activity at the perioperative period, we succeeded in hemostatic management of major surgery without significant blood loss and fluid overload. From the course of this case, we found that measuring FXI activity is superior to measuring APTT. Furthermore, we identified a novel homozygous mutation in F11 [NM_000128.3:c.1041C > A:p.(Tyr347*)] by whole exome sequencing.

Entities:  

Keywords:  Causative F11 mutation; Factor XI deficiency; Fresh frozen plasma (FFP); Hemostatic management; Major surgery; Whole exome sequencing

Mesh:

Substances:

Year:  2018        PMID: 29713955     DOI: 10.1007/s12185-018-2462-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

Review 1.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4.

Authors:  A Kato; R Asakai; E W Davie; N Aoki
Journal:  Cytogenet Cell Genet       Date:  1989

Review 3.  Current therapy for rare factor deficiencies.

Authors:  J Di Paola; D Nugent; G Young
Journal:  Haemophilia       Date:  2001-01       Impact factor: 4.287

4.  Factor XI deficiency in Ashkenazi Jews in Israel.

Authors:  R Asakai; D W Chung; E W Davie; U Seligsohn
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

5.  Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency.

Authors:  G N Pike; A M Cumming; J Thachil; C R M Hay; J Burthem; P H B Bolton-Maggs
Journal:  Haemophilia       Date:  2016-11-08       Impact factor: 4.287

6.  Molecular genetic analysis of the F11 gene in 14 Turkish patients with factor XI deficiency: identification of novel and recurrent mutations and their inheritance within families.

Authors:  Seyma Colakoglu; Turan Bayhan; Betül Tavil; Ebru Yılmaz Keskin; Volkan Cakir; Fatma Gümrük; Mualla Çetin; Selin Aytaç; Ergul Berber
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 7.  Congenital factor XI deficiency: an update.

Authors:  Stefano Duga; Ophira Salomon
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

8.  Milder progressive cerebellar atrophy caused by biallelic SEPSECS mutations.

Authors:  Kazuhiro Iwama; Masayuki Sasaki; Shinichi Hirabayashi; Chihiro Ohba; Emi Iwabuchi; Satoko Miyatake; Mitsuko Nakashima; Noriko Miyake; Shuichi Ito; Hirotomo Saitsu; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2016-02-18       Impact factor: 3.172

9.  Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate.

Authors:  P W Collins; E Goldman; P Lilley; K J Pasi; C A Lee
Journal:  Haemophilia       Date:  1995-10       Impact factor: 4.287

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.